Effect of Scopolamine Butylbromide on Clozapine-induced Hypersalivation in Schizophrenic Patients: A Case Series

다국어 초록 (Multilingual Abstract)

Clozapine has been demonstrated to be useful for treating refractory schizophrenia. However, hypersalivation occurs in 31.0- 97.4% of the patients treated with clozapine. Accordingly, some patients who are disturbed by their hypersalivation refuse to continue with clozapine treatment. This study investigated the efficacy of the anticholinergic agent scopolamine butylbromide against clozapine-induced hypersalivation. Five schizophrenia patients were coadministered scopolamine butylbromide (30-60 mg/ day) for 4 weeks. At the baseline and after 4 weeks’ treatment, we subjectively evaluated hypersalivation using a visual analog scale and objectively assessed it using the Drooling Severity Scale and Drooling Frequency Scale. As a result, improvements in the patients’ Drooling Severity Scale and Drooling Frequency Scale scores, but no improvements in their visual analog scale scores, were observed after scopolamine butylbromide treatment. These results indicate that at least some schizophrenic patients with clozapine-induced hypersalivation would benefit from scopolamine butylbromide treatment. We conclude that clozapine-induced hypersalivation is one factor of stress to patients. Subjective hypersalivation was not improved, but objective hypersalivation was, by scopolamine butylbromide treatment. However, scopolamine butylbromide and clozapine possess anticholinergic effects so clinicians should closely monitor patients who take scopolamine butylbromide.

참고문헌 (Reference)

1 Spivak B., "Trihexyphenidyl treatment of clozapineinduced hypersalivation" 12 : 213-215, 1997

2 Weiner DM., "The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine" 177 : 207-216, 2004

3 Schneider B., "Reduction of clozapine-induced hypersalivation by pirenzepine is safe" 37 : 43-45, 2004

4 Bymaster FP., "Radioreceptor binding profile of the atypical antipsychotic olanzapine" 14 : 87-96, 1996

5 Nielsen J., "Psychiatrists' attitude towards and knowledge of clozapine treatment" 24 : 965-971, 2010

6 Calderon J., "Potential use of ipatropium bromide for the treatment of clozapine-induced hypersalivation : a preliminary report" 15 : 49-52, 2000

7 Ancelin ML., "Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs : longitudinal cohort study" 332 : 455-459, 2006

8 Li Z., "N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors" 30 : 1986-1995, 2005

9 Raufman JP., "Muscarinic receptor subtype-3 gene ablation and scopolamine butylbromide treatment attenuate small intestinal neoplasia in Apcmin/+ mice" 32 : 1396-1402, 2011

10 Zeng XP., "Muscarinic m4 receptor activation by some atypical antipsychotic drugs" 321 : 349-354, 1997

11 Leung JG., "Immediate-release oxybutynin for the treatment of clozapine-induced sialorrhea" 45 : e45-, 2011

12 McKane JP., "Hyoscine patches in clozapine-induced hypersalivation" 25 : 277-, 2001

13 Kishi T., "Efficacy and tolerability of clozapine in Japanese patients with treatment-resistant schizophrenia : results from a 12-week, flexible dose study using raters masked to antipsychotic choice" 6 : 200-207, 2013

14 Tollefson GD., "Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine" 49 : 52-63, 2001

15 Praharaj SK., "Complete resolution of clozapine-induced sialorrhea with low dose trihexyphenidyl" 43 : 73-75, 2010

16 Davydov L., "Clozapine-induced hypersalivation" 34 : 662-665, 2000

17 Zorn SH., "Clozapine is a potent and selective muscarinic M4 receptor agonist" 269 : R1-R2, 1994